Identifying predictors of early trial termination: a meta-epidemiological study utilising elements of the research ethics committee evaluation
Early trial termination remains frequent. Research ethics committees (RECs) could play a role in reducing the probability of early termination. Their review process provides a window for both identifying trials at high risk of terminating prematurely and imposing preventive measures, such as design...
Saved in:
Published in | Journal of clinical epidemiology Vol. 184; p. 111832 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.08.2025
Elsevier Limited |
Subjects | |
Online Access | Get full text |
ISSN | 0895-4356 1878-5921 |
DOI | 10.1016/j.jclinepi.2025.111832 |
Cover
Abstract | Early trial termination remains frequent. Research ethics committees (RECs) could play a role in reducing the probability of early termination. Their review process provides a window for both identifying trials at high risk of terminating prematurely and imposing preventive measures, such as design modifications. This study aimed to explore whether characteristics of ethics review, alongside trial characteristics, are related to subsequent early trial termination.
This meta-epidemiological cohort study assessed 198 clinical trials approved by a Dutch REC between 2015 and 2018. Data from archived trial protocols, related study documents, and correspondence between the REC and investigators were analysed to identify predictors of early termination during ethics review.
Of the 198 trials, 69 (34.8%) terminated early, most often due to recruitment failure (n = 31, 35.2%). Several characteristics were associated with early termination, such as multicentre design (vs single centre, risk ratio [RR]: 1.89, 95% CI: 1.24–3.14), number of comments raised during ethics review (per comment, RR: 1.02, 95% CI: 1.00–1.05), and specific comments regarding privacy and confidentiality (RR: 1.21, 95% CI: 1.05–1.41) and participant information sheets (RR: 1.05, 95% CI: 1.02–1.08). Investigator sponsorship, longer review durations, and comments raised regarding privacy and confidentiality and subject selection were associated with an increased likelihood of recruitment failure, specifically.
This exploratory study showed that various characteristics of ethics review have the potential to predict early trial termination. Further studies are needed to validate and expand upon these findings.
Clinical trials sometimes end earlier than planned, often due to difficulties recruiting enough participants. When trials stop too soon, their results become less reliable. Research ethics committees (RECs) review trial plans before they begin to make sure they meet legal and ethical standards. RECs may also be able to help prevent early termination by identifying trials at high risk and recommending improvements. This study looked at 198 clinical trials approved by a Dutch REC to see if the characteristics of the ethics review process could predict which trials might stop early. The study found that about one-third of the trials ended early, most often due to recruitment problems. Trials were more likely to stop early if they involved multiple centres, received more comments from the REC, or received comments specifically about issues related to privacy, confidentiality, or the information given to participants. Recruitment problems were more common in trials that had longer review times, received comments about who was eligible to take part or issues related to privacy and confidentiality, or were run by researchers without commercial sponsorship. Overall, the findings suggest that by examining the ethics review process more closely, RECs might be able to identify and support trials at higher risk of stopping early. More research is needed to confirm these results and explore how RECs might help improve trial success.
•Around one-third of clinical trials stop early, often due to recruitment failure.•Research ethics committees may help reduce the risk of early termination.•This study showed that aspects of ethics review can help predict early termination.•Review time, number and type of comments were linked to early trial termination.•Multicenter design was linked to termination and sponsorship to recruitment failure. |
---|---|
AbstractList | Early trial termination remains frequent. Research ethics committees (RECs) could play a role in reducing the probability of early termination. Their review process provides a window for both identifying trials at high risk of terminating prematurely and imposing preventive measures, such as design modifications. This study aimed to explore whether characteristics of ethics review, alongside trial characteristics, are related to subsequent early trial termination.
This meta-epidemiological cohort study assessed 198 clinical trials approved by a Dutch REC between 2015 and 2018. Data from archived trial protocols, related study documents, and correspondence between the REC and investigators were analysed to identify predictors of early termination during ethics review.
Of the 198 trials, 69 (34.8%) terminated early, most often due to recruitment failure (n = 31, 35.2%). Several characteristics were associated with early termination, such as multicentre design (vs single centre, risk ratio [RR]: 1.89, 95% CI: 1.24-3.14), number of comments raised during ethics review (per comment, RR: 1.02, 95% CI: 1.00-1.05), and specific comments regarding privacy and confidentiality (RR: 1.21, 95% CI: 1.05-1.41) and participant information sheets (RR: 1.05, 95% CI: 1.02-1.08). Investigator sponsorship, longer review durations, and comments raised regarding privacy and confidentiality and subject selection were associated with an increased likelihood of recruitment failure, specifically.
This exploratory study showed that various characteristics of ethics review have the potential to predict early trial termination. Further studies are needed to validate and expand upon these findings.
Clinical trials sometimes end earlier than planned, often due to difficulties recruiting enough participants. When trials stop too soon, their results become less reliable. Research ethics committees (RECs) review trial plans before they begin to make sure they meet legal and ethical standards. RECs may also be able to help prevent early termination by identifying trials at high risk and recommending improvements. This study looked at 198 clinical trials approved by a Dutch REC to see if the characteristics of the ethics review process could predict which trials might stop early. The study found that about one-third of the trials ended early, most often due to recruitment problems. Trials were more likely to stop early if they involved multiple centres, received more comments from the REC, or received comments specifically about issues related to privacy, confidentiality, or the information given to participants. Recruitment problems were more common in trials that had longer review times, received comments about who was eligible to take part or issues related to privacy and confidentiality, or were run by researchers without commercial sponsorship. Overall, the findings suggest that by examining the ethics review process more closely, RECs might be able to identify and support trials at higher risk of stopping early. More research is needed to confirm these results and explore how RECs might help improve trial success. Objectives Early trial termination remains frequent. Research ethics committees (RECs) could play a role in reducing the probability of early termination. Their review process provides a window for both identifying trials at high risk of terminating prematurely and imposing preventive measures, such as design modifications. This study aimed to explore whether characteristics of ethics review, alongside trial characteristics, are related to subsequent early trial termination. Study Design and Setting This meta-epidemiological cohort study assessed 198 clinical trials approved by a Dutch REC between 2015 and 2018. Data from archived trial protocols, related study documents, and correspondence between the REC and investigators were analysed to identify predictors of early termination during ethics review. Results Of the 198 trials, 69 (34.8%) terminated early, most often due to recruitment failure ( n = 31, 35.2%). Several characteristics were associated with early termination, such as multicentre design (vs single centre, risk ratio [RR]: 1.89, 95% CI: 1.24–3.14), number of comments raised during ethics review (per comment, RR: 1.02, 95% CI: 1.00–1.05), and specific comments regarding privacy and confidentiality (RR: 1.21, 95% CI: 1.05–1.41) and participant information sheets (RR: 1.05, 95% CI: 1.02–1.08). Investigator sponsorship, longer review durations, and comments raised regarding privacy and confidentiality and subject selection were associated with an increased likelihood of recruitment failure, specifically. Conclusion This exploratory study showed that various characteristics of ethics review have the potential to predict early trial termination. Further studies are needed to validate and expand upon these findings. Plain Language Summary Clinical trials sometimes end earlier than planned, often due to difficulties recruiting enough participants. When trials stop too soon, their results become less reliable. Research ethics committees (RECs) review trial plans before they begin to make sure they meet legal and ethical standards. RECs may also be able to help prevent early termination by identifying trials at high risk and recommending improvements. This study looked at 198 clinical trials approved by a Dutch REC to see if the characteristics of the ethics review process could predict which trials might stop early. The study found that about one-third of the trials ended early, most often due to recruitment problems. Trials were more likely to stop early if they involved multiple centres, received more comments from the REC, or received comments specifically about issues related to privacy, confidentiality, or the information given to participants. Recruitment problems were more common in trials that had longer review times, received comments about who was eligible to take part or issues related to privacy and confidentiality, or were run by researchers without commercial sponsorship. Overall, the findings suggest that by examining the ethics review process more closely, RECs might be able to identify and support trials at higher risk of stopping early. More research is needed to confirm these results and explore how RECs might help improve trial success. Early trial termination remains frequent. Research ethics committees (RECs) could play a role in reducing the probability of early termination. Their review process provides a window for both identifying trials at high risk of terminating prematurely and imposing preventive measures, such as design modifications. This study aimed to explore whether characteristics of ethics review, alongside trial characteristics, are related to subsequent early trial termination. This meta-epidemiological cohort study assessed 198 clinical trials approved by a Dutch REC between 2015 and 2018. Data from archived trial protocols, related study documents, and correspondence between the REC and investigators were analysed to identify predictors of early termination during ethics review. Of the 198 trials, 69 (34.8%) terminated early, most often due to recruitment failure (n = 31, 35.2%). Several characteristics were associated with early termination, such as multicentre design (vs single centre, risk ratio [RR]: 1.89, 95% CI: 1.24–3.14), number of comments raised during ethics review (per comment, RR: 1.02, 95% CI: 1.00–1.05), and specific comments regarding privacy and confidentiality (RR: 1.21, 95% CI: 1.05–1.41) and participant information sheets (RR: 1.05, 95% CI: 1.02–1.08). Investigator sponsorship, longer review durations, and comments raised regarding privacy and confidentiality and subject selection were associated with an increased likelihood of recruitment failure, specifically. This exploratory study showed that various characteristics of ethics review have the potential to predict early trial termination. Further studies are needed to validate and expand upon these findings. Clinical trials sometimes end earlier than planned, often due to difficulties recruiting enough participants. When trials stop too soon, their results become less reliable. Research ethics committees (RECs) review trial plans before they begin to make sure they meet legal and ethical standards. RECs may also be able to help prevent early termination by identifying trials at high risk and recommending improvements. This study looked at 198 clinical trials approved by a Dutch REC to see if the characteristics of the ethics review process could predict which trials might stop early. The study found that about one-third of the trials ended early, most often due to recruitment problems. Trials were more likely to stop early if they involved multiple centres, received more comments from the REC, or received comments specifically about issues related to privacy, confidentiality, or the information given to participants. Recruitment problems were more common in trials that had longer review times, received comments about who was eligible to take part or issues related to privacy and confidentiality, or were run by researchers without commercial sponsorship. Overall, the findings suggest that by examining the ethics review process more closely, RECs might be able to identify and support trials at higher risk of stopping early. More research is needed to confirm these results and explore how RECs might help improve trial success. •Around one-third of clinical trials stop early, often due to recruitment failure.•Research ethics committees may help reduce the risk of early termination.•This study showed that aspects of ethics review can help predict early termination.•Review time, number and type of comments were linked to early trial termination.•Multicenter design was linked to termination and sponsorship to recruitment failure. AbstractObjectivesEarly trial termination remains frequent. Research ethics committees (RECs) could play a role in reducing the probability of early termination. Their review process provides a window for both identifying trials at high risk of terminating prematurely and imposing preventive measures, such as design modifications. This study aimed to explore whether characteristics of ethics review, alongside trial characteristics, are related to subsequent early trial termination. Study Design and SettingThis meta-epidemiological cohort study assessed 198 clinical trials approved by a Dutch REC between 2015 and 2018. Data from archived trial protocols, related study documents, and correspondence between the REC and investigators were analysed to identify predictors of early termination during ethics review. ResultsOf the 198 trials, 69 (34.8%) terminated early, most often due to recruitment failure ( n = 31, 35.2%). Several characteristics were associated with early termination, such as multicentre design (vs single centre, risk ratio [RR]: 1.89, 95% CI: 1.24–3.14), number of comments raised during ethics review (per comment, RR: 1.02, 95% CI: 1.00–1.05), and specific comments regarding privacy and confidentiality (RR: 1.21, 95% CI: 1.05–1.41) and participant information sheets (RR: 1.05, 95% CI: 1.02–1.08). Investigator sponsorship, longer review durations, and comments raised regarding privacy and confidentiality and subject selection were associated with an increased likelihood of recruitment failure, specifically. ConclusionThis exploratory study showed that various characteristics of ethics review have the potential to predict early trial termination. Further studies are needed to validate and expand upon these findings. Plain Language SummaryClinical trials sometimes end earlier than planned, often due to difficulties recruiting enough participants. When trials stop too soon, their results become less reliable. Research ethics committees (RECs) review trial plans before they begin to make sure they meet legal and ethical standards. RECs may also be able to help prevent early termination by identifying trials at high risk and recommending improvements. This study looked at 198 clinical trials approved by a Dutch REC to see if the characteristics of the ethics review process could predict which trials might stop early. The study found that about one-third of the trials ended early, most often due to recruitment problems. Trials were more likely to stop early if they involved multiple centres, received more comments from the REC, or received comments specifically about issues related to privacy, confidentiality, or the information given to participants. Recruitment problems were more common in trials that had longer review times, received comments about who was eligible to take part or issues related to privacy and confidentiality, or were run by researchers without commercial sponsorship. Overall, the findings suggest that by examining the ethics review process more closely, RECs might be able to identify and support trials at higher risk of stopping early. More research is needed to confirm these results and explore how RECs might help improve trial success. |
ArticleNumber | 111832 |
Author | Buijs, Jeroen T. Groenwold, Rolf H.H. Pet, Lodewijk A. Siegerink, Bob Dekkers, Olaf M. Jansen, Marieke S. |
Author_xml | – sequence: 1 givenname: Marieke S. orcidid: 0000-0001-5669-2593 surname: Jansen fullname: Jansen, Marieke S. email: m.s.jansen@lumc.nl organization: Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands – sequence: 2 givenname: Lodewijk A. orcidid: 0000-0002-2792-4460 surname: Pet fullname: Pet, Lodewijk A. organization: Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands – sequence: 3 givenname: Jeroen T. surname: Buijs fullname: Buijs, Jeroen T. organization: Medical Research Ethics Committee Leiden The Hague Delft, Leiden, The Netherlands – sequence: 4 givenname: Bob orcidid: 0000-0002-8454-9142 surname: Siegerink fullname: Siegerink, Bob organization: Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands – sequence: 5 givenname: Rolf H.H. orcidid: 0000-0001-9238-6999 surname: Groenwold fullname: Groenwold, Rolf H.H. organization: Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands – sequence: 6 givenname: Olaf M. surname: Dekkers fullname: Dekkers, Olaf M. organization: Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40368224$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkstO3TAQhq0KVA60r4AsdZ1TX3PpomqFekFC6gJYW4494ThN4lPbQcpL8Mx1OMCii7Yrb775xjP_nKKjyU-A0DklW0po-b7f9mZwE-zdlhEmt5TSmrNXaEPrqi5kw-gR2pC6kYXgsjxBpzH2hNCKVPI1OhGElzVjYoMeLi1MyXWLm-7wPoB1JvkQse8w6DAsOAWnB5wgjG7SyfnpA9Z4hKSL3NvC6Pzg75zJTEyzXfCc3ODiaoMBxux-dKUd4AAxK80OQ9o5E7Hx4-hSAsBwr4f5Uf4GHXd6iPD26T1Dt1-_3Fx8L65-fLu8-HxVGFGRVJRSiKpqmeTCNsxQwruG1h20wtrGtrwBpgkHTUlbMdESqm1Laq07Q42BsuJn6N3Buw_-1wwxqd7PYcotFWeCMklpxTN1_kTN7QhW7YMbdVjU8_oyUB4AE3yMAboXhBK15qR69ZyTWnNSh5xy4adDIeQh7x0EFY2DyeT9BzBJWe_-rfj4h2Kl1iR-wgLxZR6qIlNEXa_HsN4Ck_kOStn8XfA_P_gNNGXL2A |
Cites_doi | 10.1001/jama.2014.1361 10.1177/1740774514558307 10.1136/medethics-2011-100020 10.1056/EVIDoa2300003 10.1186/s13063-021-05818-0 10.1371/journal.pmed.1003980 10.1136/jme.2002.002105 10.1186/s12874-022-01617-6 10.1590/S1807-59322009000900002 10.1136/ebmed-2017-110713 10.1097/EDE.0b013e31818131e7 10.1186/s13063-019-3957-4 10.1186/1472-6939-15-83 10.1136/jme.25.3.274 |
ContentType | Journal Article |
Copyright | 2025 The Author(s) The Author(s) Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved. |
Copyright_xml | – notice: 2025 The Author(s) – notice: The Author(s) – notice: Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved. |
DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QL 7QP 7T2 7T7 7TK 7U7 7U9 8FD C1K FR3 H94 K9. M7N NAPCQ P64 |
DOI | 10.1016/j.jclinepi.2025.111832 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Health and Safety Science Abstracts (Full archive) Industrial and Applied Microbiology Abstracts (Microbiology A) Neurosciences Abstracts Toxicology Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Virology and AIDS Abstracts Technology Research Database Toxicology Abstracts ProQuest Health & Medical Complete (Alumni) Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management Nursing & Allied Health Premium Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts Health & Safety Science Abstracts Engineering Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Calcium & Calcified Tissue Abstracts |
DatabaseTitleList | MEDLINE Virology and AIDS Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1878-5921 |
EndPage | 111832 |
ExternalDocumentID | 40368224 10_1016_j_jclinepi_2025_111832 S0895435625001659 1_s2_0_S0895435625001659 |
Genre | Journal Article |
GeographicLocations | Netherlands |
GeographicLocations_xml | – name: Netherlands |
GroupedDBID | --- --K --M -~X .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29K 4.4 457 4CK 4G. 53G 5GY 5RE 5VS 7-5 71M 7RV 7X7 88E 8AO 8C1 8FI 8FJ 8G5 8P~ 9JM 9JO AABNK AAEDT AAEDW AAFJI AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAWTL AAXKI AAXUO AAYJJ AAYWO ABBQC ABFNM ABIVO ABJNI ABLJU ABMAC ABMMH ABMZM ABOCM ABUWG ABWVN ABXDB ACDAQ ACGFS ACIEU ACIUM ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFFNX AFJKZ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AHHHB AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX AOMHK APXCP AQUVI ASPBG AVARZ AVWKF AXJTR AZFZN AZQEC BENPR BKEYQ BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CS3 D-I DU5 DWQXO EBS EFJIC EFKBS EFLBG EJD EMOBN EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HEH HMCUK HMK HMO HVGLF HZ~ IHE J1W KOM L7B M0T M1P M29 M2O M3W M41 MO0 N9A NAPCQ O-L O9- OAUVE OD~ OHT OO0 OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQQKQ PRBVW PROAC PSQYO PUEGO Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSB SSH SSO SSZ SV3 T5K UAP UKHRP WOW WUQ X7M XPP YHZ Z5R ZGI ~G- AFCTW AGRNS ALIPV RIG 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QL 7QP 7T2 7T7 7TK 7U7 7U9 8FD C1K FR3 H94 K9. M7N P64 |
ID | FETCH-LOGICAL-c470t-654477b2534d92c103f918feb4dd9db39e2a03ea10b724b01adb08aafc1cce673 |
IEDL.DBID | AIKHN |
ISSN | 0895-4356 |
IngestDate | Thu Aug 21 03:50:36 EDT 2025 Tue Sep 09 02:32:19 EDT 2025 Wed Aug 27 16:39:41 EDT 2025 Sat Sep 06 17:16:48 EDT 2025 Fri Jun 27 03:51:14 EDT 2025 Mon Sep 08 07:22:08 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Clinical trials Early termination Research ethics committee Institutional review board Ethics approval Premature discontinuation |
Language | English |
License | This is an open access article under the CC BY license. Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c470t-654477b2534d92c103f918feb4dd9db39e2a03ea10b724b01adb08aafc1cce673 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 |
ORCID | 0000-0002-8454-9142 0000-0001-5669-2593 0000-0002-2792-4460 0000-0001-9238-6999 |
OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0895435625001659 |
PMID | 40368224 |
PQID | 3241251173 |
PQPubID | 105585 |
PageCount | 1 |
ParticipantIDs | proquest_journals_3241251173 pubmed_primary_40368224 crossref_primary_10_1016_j_jclinepi_2025_111832 elsevier_sciencedirect_doi_10_1016_j_jclinepi_2025_111832 elsevier_clinicalkeyesjournals_1_s2_0_S0895435625001659 elsevier_clinicalkey_doi_10_1016_j_jclinepi_2025_111832 |
PublicationCentury | 2000 |
PublicationDate | 2025-08-01 |
PublicationDateYYYYMMDD | 2025-08-01 |
PublicationDate_xml | – month: 08 year: 2025 text: 2025-08-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Elmsford |
PublicationTitle | Journal of clinical epidemiology |
PublicationTitleAlternate | J Clin Epidemiol |
PublicationYear | 2025 |
Publisher | Elsevier Inc Elsevier Limited |
Publisher_xml | – name: Elsevier Inc – name: Elsevier Limited |
References | Kent (bib12) 1999; 25 Ioannidis (bib3) 2008; 19 Murad, Wang (bib9) 2017; 22 van Lent, Rongen, Out (bib11) 2014; 15 Kelleher, Stanton, Vale, Smith (bib15) 2013; 106 Bueno, Brevidelli, Cocarelli, Santos, Ferraz, Mion (bib14) 2009; 64 bib10 van Zwet, Gelman, Greenland, Imbens, Schwab, Goodman (bib4) 2024; 3 Speich, Gryaznov, Busse, Gloy, Lohner, Klatte (bib2) 2022; 19 Gloy, Speich, Griessbach (bib16) 2022; 22 Briel, Speich, von Elm, Gloy (bib6) 2019; 20 Damen, van Agt, de Boo, Huysmans (bib8) 2012; 38 Kasenda, von Elm, You, Blümle, Tomonaga, Saccilotto (bib1) 2014; 311 Carlisle, Kimmelman, Ramsay, MacKinnon (bib7) 2015; 12 Briel, Elger, McLennan, Schandelmaier, von Elm, Satalkar (bib5) 2021; 22 Sansone, McDonald, Hanley, Sellbom, Gaither (bib13) 2004; 30 Briel (10.1016/j.jclinepi.2025.111832_bib6) 2019; 20 Gloy (10.1016/j.jclinepi.2025.111832_bib16) 2022; 22 Bueno (10.1016/j.jclinepi.2025.111832_bib14) 2009; 64 Kent (10.1016/j.jclinepi.2025.111832_bib12) 1999; 25 van Lent (10.1016/j.jclinepi.2025.111832_bib11) 2014; 15 Damen (10.1016/j.jclinepi.2025.111832_bib8) 2012; 38 Kelleher (10.1016/j.jclinepi.2025.111832_bib15) 2013; 106 Sansone (10.1016/j.jclinepi.2025.111832_bib13) 2004; 30 Ioannidis (10.1016/j.jclinepi.2025.111832_bib3) 2008; 19 Kasenda (10.1016/j.jclinepi.2025.111832_bib1) 2014; 311 Speich (10.1016/j.jclinepi.2025.111832_bib2) 2022; 19 Briel (10.1016/j.jclinepi.2025.111832_bib5) 2021; 22 van Zwet (10.1016/j.jclinepi.2025.111832_bib4) 2024; 3 Carlisle (10.1016/j.jclinepi.2025.111832_bib7) 2015; 12 Murad (10.1016/j.jclinepi.2025.111832_bib9) 2017; 22 |
References_xml | – volume: 22 start-page: 844 year: 2021 ident: bib5 article-title: Exploring reasons for recruitment failure in clinical trials: a qualitative study with clinical trial stakeholders in Switzerland, Germany, and Canada publication-title: Trials – ident: bib10 article-title: Your research: is it subject to the WMO or not? – volume: 15 start-page: 83 year: 2014 ident: bib11 article-title: Shortcomings of protocols of drug trials in relation to sponsorship as identified by Research Ethics Committees: analysis of comments raised during ethical review publication-title: BMC Med Ethics – volume: 64 start-page: 831 year: 2009 end-page: 836 ident: bib14 article-title: Reasons for resubmission of research projects to the research ethics committee of a university hospital in Sao Paulo, Brazil publication-title: Clinics (Sao Paulo) – volume: 12 start-page: 77 year: 2015 end-page: 83 ident: bib7 article-title: Unsuccessful trial accrual and human subjects protections: an empirical analysis of recently closed trials publication-title: Clin Trials – volume: 19 start-page: e1003980 year: 2022 ident: bib2 article-title: Nonregistration, discontinuation, and nonpublication of randomized trials: a repeated metaresearch analysis publication-title: PLoS Med – volume: 22 start-page: 139 year: 2017 end-page: 142 ident: bib9 article-title: Guidelines for reporting meta-epidemiological methodology research publication-title: Evid Based Med – volume: 22 start-page: 142 year: 2022 ident: bib16 article-title: Scoping review and characteristics of publicly available checklists for assessing clinical trial feasibility publication-title: BMC Med Res Methodol – volume: 311 start-page: 1045 year: 2014 end-page: 1051 ident: bib1 article-title: Prevalence, characteristics, and publication of discontinued randomized trials publication-title: JAMA – volume: 20 start-page: 800 year: 2019 ident: bib6 article-title: Comparison of randomized controlled trials discontinued or revised for poor recruitment and completed trials with the same research question: a matched qualitative study publication-title: Trials – volume: 38 start-page: 413 year: 2012 end-page: 416 ident: bib8 article-title: Terminating clinical trials without sufficient subjects publication-title: J Med Ethics – volume: 106 start-page: 184 year: 2013 end-page: 185 ident: bib15 article-title: Recurring themes arising during medical research ethics committee review publication-title: Ir Med J – volume: 19 start-page: 640 year: 2008 end-page: 648 ident: bib3 article-title: Why most discovered true associations are inflated publication-title: Epidemiology – volume: 25 start-page: 274 year: 1999 end-page: 277 ident: bib12 article-title: Responses by four local research ethics committees to submitted proposals publication-title: J Med Ethics – volume: 30 start-page: 308 year: 2004 end-page: 310 ident: bib13 article-title: The stipulations of one institutional review board: a five year review publication-title: J Med Ethics – volume: 3 year: 2024 ident: bib4 article-title: A new look at P values for randomized clinical trials publication-title: NEJM Evid – volume: 311 start-page: 1045 issue: 10 year: 2014 ident: 10.1016/j.jclinepi.2025.111832_bib1 article-title: Prevalence, characteristics, and publication of discontinued randomized trials publication-title: JAMA doi: 10.1001/jama.2014.1361 – volume: 12 start-page: 77 issue: 1 year: 2015 ident: 10.1016/j.jclinepi.2025.111832_bib7 article-title: Unsuccessful trial accrual and human subjects protections: an empirical analysis of recently closed trials publication-title: Clin Trials doi: 10.1177/1740774514558307 – volume: 38 start-page: 413 issue: 7 year: 2012 ident: 10.1016/j.jclinepi.2025.111832_bib8 article-title: Terminating clinical trials without sufficient subjects publication-title: J Med Ethics doi: 10.1136/medethics-2011-100020 – volume: 3 issue: 1 year: 2024 ident: 10.1016/j.jclinepi.2025.111832_bib4 article-title: A new look at P values for randomized clinical trials publication-title: NEJM Evid doi: 10.1056/EVIDoa2300003 – volume: 22 start-page: 844 issue: 1 year: 2021 ident: 10.1016/j.jclinepi.2025.111832_bib5 article-title: Exploring reasons for recruitment failure in clinical trials: a qualitative study with clinical trial stakeholders in Switzerland, Germany, and Canada publication-title: Trials doi: 10.1186/s13063-021-05818-0 – volume: 19 start-page: e1003980 issue: 4 year: 2022 ident: 10.1016/j.jclinepi.2025.111832_bib2 article-title: Nonregistration, discontinuation, and nonpublication of randomized trials: a repeated metaresearch analysis publication-title: PLoS Med doi: 10.1371/journal.pmed.1003980 – volume: 30 start-page: 308 issue: 3 year: 2004 ident: 10.1016/j.jclinepi.2025.111832_bib13 article-title: The stipulations of one institutional review board: a five year review publication-title: J Med Ethics doi: 10.1136/jme.2002.002105 – volume: 22 start-page: 142 issue: 1 year: 2022 ident: 10.1016/j.jclinepi.2025.111832_bib16 article-title: Scoping review and characteristics of publicly available checklists for assessing clinical trial feasibility publication-title: BMC Med Res Methodol doi: 10.1186/s12874-022-01617-6 – volume: 64 start-page: 831 issue: 9 year: 2009 ident: 10.1016/j.jclinepi.2025.111832_bib14 article-title: Reasons for resubmission of research projects to the research ethics committee of a university hospital in Sao Paulo, Brazil publication-title: Clinics (Sao Paulo) doi: 10.1590/S1807-59322009000900002 – volume: 22 start-page: 139 issue: 4 year: 2017 ident: 10.1016/j.jclinepi.2025.111832_bib9 article-title: Guidelines for reporting meta-epidemiological methodology research publication-title: Evid Based Med doi: 10.1136/ebmed-2017-110713 – volume: 19 start-page: 640 issue: 5 year: 2008 ident: 10.1016/j.jclinepi.2025.111832_bib3 article-title: Why most discovered true associations are inflated publication-title: Epidemiology doi: 10.1097/EDE.0b013e31818131e7 – volume: 106 start-page: 184 issue: 6 year: 2013 ident: 10.1016/j.jclinepi.2025.111832_bib15 article-title: Recurring themes arising during medical research ethics committee review publication-title: Ir Med J – volume: 20 start-page: 800 issue: 1 year: 2019 ident: 10.1016/j.jclinepi.2025.111832_bib6 article-title: Comparison of randomized controlled trials discontinued or revised for poor recruitment and completed trials with the same research question: a matched qualitative study publication-title: Trials doi: 10.1186/s13063-019-3957-4 – volume: 15 start-page: 83 year: 2014 ident: 10.1016/j.jclinepi.2025.111832_bib11 article-title: Shortcomings of protocols of drug trials in relation to sponsorship as identified by Research Ethics Committees: analysis of comments raised during ethical review publication-title: BMC Med Ethics doi: 10.1186/1472-6939-15-83 – volume: 25 start-page: 274 issue: 3 year: 1999 ident: 10.1016/j.jclinepi.2025.111832_bib12 article-title: Responses by four local research ethics committees to submitted proposals publication-title: J Med Ethics doi: 10.1136/jme.25.3.274 |
SSID | ssj0017075 |
Score | 2.4764073 |
Snippet | Early trial termination remains frequent. Research ethics committees (RECs) could play a role in reducing the probability of early termination. Their review... AbstractObjectivesEarly trial termination remains frequent. Research ethics committees (RECs) could play a role in reducing the probability of early... Objectives Early trial termination remains frequent. Research ethics committees (RECs) could play a role in reducing the probability of early termination.... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 111832 |
SubjectTerms | Clinical trials Clinical Trials as Topic - ethics Clinical Trials as Topic - statistics & numerical data Correspondence Design Design modifications Early termination Early Termination of Clinical Trials - ethics Early Termination of Clinical Trials - statistics & numerical data Epidemiologic Studies Epidemiology Ethical standards Ethics approval Ethics Committees, Research - standards Ethics Committees, Research - statistics & numerical data Humans Institutional review board Internal Medicine Medical research Netherlands Patient Selection Premature discontinuation Privacy Recruitment Reimbursement Research ethics Research ethics committee Risk Variables |
Title | Identifying predictors of early trial termination: a meta-epidemiological study utilising elements of the research ethics committee evaluation |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0895435625001659 https://www.clinicalkey.es/playcontent/1-s2.0-S0895435625001659 https://dx.doi.org/10.1016/j.jclinepi.2025.111832 https://www.ncbi.nlm.nih.gov/pubmed/40368224 https://www.proquest.com/docview/3241251173 |
Volume | 184 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NT9wwEB3BIlW9VPR7C0U-9Go2dpw47g0h0LYVXFokbpadTNSsyrJi02t_Ar8ZT-wsVBVS1R5jxXHiGc88x_NmAD5g7gIMR81dqz1XWDpemcrzqsHWBXcvvCTu8Nl5Ob9Qny-Lyy04HrkwFFaZbH-06YO1Ti2zNJuzVdfNvmaVKYKzDwCecEthtmFH5qYsJrBz9OnL_HxzmKBjvl26n1OHB0ThxeGCGIi46sJWURZkQKpcPuajHsOggy863YVnCUSyo_iez2ELly_gyVk6Jn8Jt5F-O1CY2OqG2qmoDrtuGVJCYzbU6mApEIZE85E5doW943hfMZbEx4b0syxo54-O_iowjOHmw7MCdmQpWdB3hkPgPAvzeNX1PSK7zyP-Ci5OT74dz3kqvMBrpbOel4VSWntZ5KoxshZZ3hpRtehV05jG5waly3J0IvNaKp8J1_iscq6tRV1jqfPXMFleL_EtsGA-S2_QlZUzytCZZenDnjIoiMZCNvUUZuNU21XMr2HHwLOFHYVjSTg2CmcKepSIHdmjwd7Z4AL-rSeu07JdW2HX0mb2D9Wagtn0_E07_2rU_VFt7GagAGMJWQqdT-FNVKXN56sAKii2991_DLoHT-kqRiruw6S_-YnvA3rq_QFsH_4SB2mN3AFCGRzs |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB6VIgEXVN5bCvjA1d34kTjmhiqqBbq90Eq9WXYyEVm121U3XPkJ_OZ64mQLqiohuCZ2nHjGM5_jb2YA3qPyEYaj4b4xgWssPC9tGXhZY-OjuxdBUuzw_LiYneovZ_nZFhyMsTBEqxxsf7LpvbUerkyH2Zyu2nb6LSttHp19BPCEW3J7D-7rXBni9e3_3PA8hEnZdqk1p-a_hQkv9hcUf4irNm4UZU7mo1TyLg91FwLtPdHhDjweICT7mN7yCWzh8ik8mA-H5M_gVwq-7QOY2OqKrlNJHXbZMKR0xqyv1MEGGgwJ5gPz7AI7z_GmXiwJj_XJZ1nUzfOW_ikwTGTz_lkRObIhVdB3hj1tnsVZvGi7DpHdZBF_DqeHn04OZnwou8ArbbKOF7nWxgSZK11bWYlMNVaUDQZd17YOyqL0mUIvsmCkDpnwdchK75tKVBUWRr2A7eXlEl8Bi8azCBZ9UXqrLZ1YFiHuKKN6GMxlXU1gOk61W6XsGm6knS3cKBxHwnFJOBMwo0TcGDsarZ2LDuDfeuJ6WLRrJ9xauszdUqwJ2E3PP3Tzr0bdG9XGbQaKIJZwpTBqAi-TKm0-X0dIQcze3f8Y9B08nJ3Mj9zR5-Ovr-ER3UmcxT3Y7q5-4JuIo7rwtl8n17UIHbc |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Identifying+predictors+of+early+trial+termination%3A+a+meta-epidemiological+study+utilising+elements+of+the+research+ethics+committee+evaluation&rft.jtitle=Journal+of+clinical+epidemiology&rft.au=Jansen%2C+Marieke+S.&rft.au=Pet%2C+Lodewijk+A.&rft.au=Buijs%2C+Jeroen+T.&rft.au=Siegerink%2C+Bob&rft.date=2025-08-01&rft.pub=Elsevier+Inc&rft.issn=0895-4356&rft.volume=184&rft_id=info:doi/10.1016%2Fj.jclinepi.2025.111832&rft.externalDocID=S0895435625001659 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F08954356%2Fcov200h.gif |